Trial Profile
A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naive Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 02 Aug 2021 Status changed from recruiting to completed.
- 05 Jul 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jun 2019).
- 23 Jul 2019 Planned End Date changed from 31 Dec 2019 to 18 Dec 2019.